Clinical interviews predict postpartum depression

For pregnant women, predictive medicine may provide guidance in identifying their risks of developing postpartum depression. Published in the Journal of Clinical Psychiatry, a recent study tested the effectiveness of clinical interviews in pinpointing those at elevated risk of depression after birth.

While women with a history of depression are more susceptible to developing symptoms postpartum, evidence is scare predicting mothers who develop postpartum depression when they did not experience depression before birth. Researchers from the University of California, Los Angeles, led by Rita Anshu Suri, MD, psychiatrist at UCLA, tested how clinical interviews could identify women more prone to developing postpartum depression.

The study, which spanned from April 2003 to March 2006, included 343 pregnant women between 12 and 36 weeks of gestation, who were not suffering from depression during pregnancy but had a previous history of major depressive disorder. Patients visited a psychiatrist both 60 days before and after giving birth. During these visits, psychiatrists asked patients about their daily lives including work, insomnia and suicidal ideation.

Results revealed that of the women not experiencing depression during pregnancy but had a history of major depressive disorder, only 11 percent developed postpartum depression. This rate was significantly lower than the 40 percent found in other studies. Question regarding work activities, insomnia and suicidal thoughts were effective in identifying women more prone to develop postpartum depression. Administering preventive antidepressants had no effect on whether women developed postpartum depression.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.